HDAC2 and non-small cell lung carcinoma: The down‐regulation of HDAC2 decreased M2‐like macrophage population.[143] Accordingly, M1‐like macrophages were elevated, which benefited to the increase of ROS level in tumors and subsequent regulation of the intracellular redox balance through ROS/NOX3/MsrA axis, leading to resensitization of the EGFRT790M‐positive NSCLC to gefitinib and amplified anti‐tumor effects.